Literature DB >> 16982862

Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease.

Tsunekazu Oikawa1, Yosuke Kamimura, Hisaya Akiba, Hideo Yagita, Ko Okumura, Hiroki Takahashi, Mikio Zeniya, Hisao Tajiri, Miyuki Azuma.   

Abstract

Tim-3, a member of the T cell Ig mucin (TIM) family regulates effector Th1 responses. We examined Tim-3 and its ligand expression as well as the effects of anti-Tim-3 mAb treatment in a murine model of acute graft-vs-host disease (aGVHD). In mice with aGVHD, Tim-3 expression was markedly up-regulated on splenic and hepatic CD4+ and CD8+ T cells, dendritic cells (DCs), and macrophages, and this was especially dramatic in hepatic CD8+ T cells. Both donor- and host-derived CD8+ T cells induced similar levels of Tim-3. Tim-3 ligand expression was also up-regulated in splenic T cells, DCs, and macrophages, but not in the hepatic lymphocytes. The administration of anti-Tim-3 mAbs accelerated aGVHD, as demonstrated by body weight loss, reduction in total splenocyte number, and infiltration of lymphocytes in the liver. IFN-gamma expression by splenic and hepatic CD4+ and CD8+ T cells was significantly augmented by anti-Tim-3 mAb treatment. In addition, the cytotoxicity against host alloantigen by donor CD8+ T cells was enhanced. These results demonstrate that the anti-Tim-3 treatment in aGVHD augmented the activation of effector T cells expressing IFN-gamma or exerting cytotoxicity. Our results suggest that Tim-3 may play a crucial role in the regulation of CD8+ T cells responsible for the maintenance of hepatic homeostasis and tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982862     DOI: 10.4049/jimmunol.177.7.4281

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

Authors:  Álvaro de Mingo Pulido; Alycia Gardner; Shandi Hiebler; Hatem Soliman; Hope S Rugo; Matthew F Krummel; Lisa M Coussens; Brian Ruffell
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

2.  Tim-3 is differently expressed in genetically susceptible C57BL/6 and resistant BALB/c mice during oral infection with Toxoplasma gondii.

Authors:  L C Berrocal Almanza; M Muñoz; A A Kühl; T Kamradt; M M Heimesaat; O Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-09-23

3.  Participation of T cell immunoglobulin and mucin domain-3 (TIM-3) and its ligand (galectin-9) in the pathogenesis of active generalized vitiligo.

Authors:  Manoj Kumar Tembhre; Anita Singh Parihar; Alpana Sharma; Somesh Gupta; Parthaprasad Chattopadhyay; Vinod Kumar Sharma
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

4.  Antitumor effect of membrane-type Tim-3 on hepatocellular carcinoma Hepa1-6 cells of ICR mice.

Authors:  Ju Liu; Haiying Sun; Dan Shen; Mingmin Wang; Zirong Wen
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

5.  Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.

Authors:  Jinhua Piao; Yosuke Kamimura; Hideyuki Iwai; Yujia Cao; Keisuke Kikuchi; Masaaki Hashiguchi; Taro Masunaga; Hongsi Jiang; Kouichi Tamura; Shimon Sakaguchi; Miyuki Azuma
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

Review 6.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

7.  Lack of association of TIM3 polymorphisms and allergic phenotypes.

Authors:  Jian Zhang; Denise Daley; Loubna Akhabir; Dorota Stefanowicz; Moira Chan-Yeung; Allan B Becker; Catherine Laprise; Peter D Paré; Andrew J Sandford
Journal:  BMC Med Genet       Date:  2009-06-30       Impact factor: 2.103

8.  Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma.

Authors:  Hongying Zheng; Xingqing Guo; Qingwu Tian; Hui Li; Yuanqi Zhu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

9.  Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Authors:  Encheng Zhou; Qing Huang; Ji Wang; Chengfeng Fang; Leilei Yang; Min Zhu; Jianhui Chen; Lihua Chen; Milian Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  The Binding Properties of Glycosylated and Non-Glycosylated Tim-3 Molecules on CD4CD25 T Cells.

Authors:  Mi Jin Lee; Yoo Mi Heo; Seung-Ho Hong; Kyongmin Kim; Sun Park
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.